RAF kinase

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Marc Jacobs Fragrances Partners With The Center and Akt on TikTok to Support the LGBTQIA+ Community

Retrieved on: 
Friday, June 3, 2022
Luxury, Other Retail, LGBTQ+, Specialty, Philanthropy, Fashion, Fund Raising, Consumer, Other Philanthropy, Retail, Jewellery, Jacobs, Time, RAF kinase, Beauty, LinkedIn, Ageing, Partnership, Awareness, Organization, Center, Ladyfag, Multimedia, The Center, Skin, COTY, Coty, Homelessness, Risk, Employment, Health, NYSE, Lesbian, Gay, Bisexual & Transgender Community Center, Wrist, Freedom, AIDS, Culture, Transgender, Family, Instagram, TikTok, Organic, London Pride, Education, Protein kinase B, Safety, Tourism, Perfume, Pride

The brand will support and drive awareness for The Center and akt through Pride-focused TikTok campaigns in both countries.

Key Points: 
  • The brand will support and drive awareness for The Center and akt through Pride-focused TikTok campaigns in both countries.
  • In the UK, TikTok creator partners will enable in-app donations for akt beginning July 2nd to coincide with London Pride.
  • This Pride marks a second year of Marc Jacobs Fragrances support for The Center and the launch of an ongoing partnership with akt.
  • Marc Jacobs Fragrances has also committed to continuing support for both non-profit organizations in June 2023.

Asana BioSciences to Present Phase 1 Clinical Safety and Efficacy Data of Oral, Once-Weekly, ASN007, a Novel ERK 1/2 Inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

Retrieved on: 
Thursday, October 24, 2019
Research, FDA, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Enzymes, Signal transduction, Protein kinases, Extracellular signal-regulated kinases, Mitogen-activated protein kinase, MEK inhibitor, BRAF, Melanoma, KRAS, Binimetinib, RAF kinase, ASN007, Asana BioSciences, LLC

It is a potent inhibitor of the extracellular-signal-regulated kinases ERK1 and ERK2, which are key players in the RAS/RAF/MEK/ERK (MAPK) signaling pathway.

Key Points: 
  • It is a potent inhibitor of the extracellular-signal-regulated kinases ERK1 and ERK2, which are key players in the RAS/RAF/MEK/ERK (MAPK) signaling pathway.
  • ASN007 shows activity in KRAS-driven models, irrespective of subtype mutation, and BRAF models, including RAF/MEK inhibitor-resistant melanoma.
  • ASN007 has a long target residence time and shows activity in preclinical models using an intermittent dosing schedule.
  • Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.

BRAFV600 Mutation Inhibiotors - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 22, 2019
Health, Pharmaceutical, Protein kinases, Oncogenes, Serine/threonine-specific protein kinase, BRAF, c-Raf, RAF kinase

The "BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors development.
  • Pipeline Products covered across the following Developmental Stages:
    Descriptive coverage of pipeline development activities for BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
  • Pipeline Therapeutics assessment of products for BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors
    The report assesses the active BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors pipeline products by developmental stage, product type, molecule type, and administration route.